MBRX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -0.07. Updated 2026-07-23.
Moleculin Biotech (MBRX) Research Hub
Moleculin Biotech (MBRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.715 USD (-6.54%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.07, market cap 0.01B. This hub links to the full technical, earnings and options research available for MBRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.715 USD (-6.54%) |
| 52-week range | 0.3123 USD – 3.55 USD |
| Trend regime | Range |
| 14-day RSI | 80.7 (Overbought) |
| Trailing P/E | -0.07 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
Available research for MBRX
Covered Call on MBRX: how it works, illustrative setup around the real 0.715 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MBRX: how it works, illustrative setup around the real 0.715 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MBRX: how it works, illustrative setup around the real 0.715 USD price, max profit/loss, breakeven and when to use it. Educational.
MBRX technical analysis: range, last 0.715 USD, RSI 80.7, 52w range 0.3123 USD–3.55 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MBRX in?
Moleculin Biotech (MBRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MBRX in an uptrend or downtrend?
As of 2026-09-11, MBRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MBRX's trailing P/E ratio?
MBRX's trailing P/E is -0.07, with a market cap of 0.01B. See the earnings research page for full valuation detail.